Lipegfilgrastim
| Lipegfilgrastim | ||
|---|---|---|
| Mass / length primary structure | 39 kDa | |
| Drug information | ||
| ATC code | L03 AA14 | |
| Drug class | Growth factor | |
Lipegfilgrastim (trade name Lonquex ; manufacturer Merckle Biotec / Teva Pharmaceutical Industries ) is a recombinant , PEGylated human granulocyte colony-stimulating factor (G-CSF) that stimulates the formation of leukocytes . Lipegfilgrastim is an extended-duration form of filgrastim that is based on decreased excretion by the kidney.
Clinical information
Application areas (indications)
Lipegfilgrastim is used after chemotherapy to shorten the duration of neutropenia and to reduce the occurrence of febrile neutropenia (low number of white blood cells with a fever).
Type and duration of application
The medicine is given as a single subcutaneous injection using a pre-filled syringe.
Adverse effects (side effects)
The most common side effects are temporary pain in the musculoskeletal system (see also NW of G-CSF ).
Pharmacological properties
Mechanism of action (pharmacodynamics)
Like filgrastim, lipegfilgrastim binds to the G-CSF receptor. This causes an increase in the number of neutrophils in the blood.
Absorption and distribution in the body (pharmacokinetics)
The mean half-life is in a range of about 32 to 62 hours.
Other Information
Chemical and pharmaceutical information
Lipegfilgrastim is a covalent conjugate of filgrastim with a single methoxypolyethylene glycol (PEG) molecule via a carbohydrate linker made up of glycine , N-acetylneuraminic acid and N-acetylgalactosamine .
Individual evidence
- ↑ a b c Summary of Product Characteristics , accessed December 26, 2015.
- ↑ European public assessment report (EPAR) for Lonquex , EPAR of the European Medicines Agency (EMA) , English, accessed on December 26, 2015.
Trade names
Lonquex (EU)
